First Horizon Corporation’s Alnylam Pharmaceuticals ALNY Stock Holding History

First Horizon Corporation’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.3K	Buy	114 +1	+0.9%	+$302	﹤0.01%	820
2026 Q1	$37.4K	Sell	113 -50	-31%	-$17K	﹤0.01%	716
2025 Q4	$64.8K	Buy	163 +28	+21%	+$12.4K	﹤0.01%	608
2025 Q3	$61.6K	Buy	+135	New	+$55K	﹤0.01%	571
2021 Q2	$1K	Hold	9	–	–	﹤0.01%	978
2021 Q1	$1K	Hold	9	–	–	﹤0.01%	958
2020 Q4	$1K	Hold	9	–	–	﹤0.01%	949
2020 Q3	$1K	Buy	+9	New	+$1.28K	﹤0.01%	921

Other funds holding ALNY

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

First Horizon Corporation's ALNY Position: Q2 2026 in Review

First Horizon Corporation increased its Alnylam Pharmaceuticals (ALNY) stake by 0.88% in Q2 2026, buying an estimated $302 and bringing the position to 114 shares worth $34.3K. The position accounts for ﹤0.01% of the portfolio, ranked #820.

First Horizon Corporation first reported a position in ALNY in Q3 2020 and has held it in 8 quarters since. The position peaked at $64.8K in Q4 2025. 262 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

First Horizon Corporation held 114 shares of Alnylam Pharmaceuticals worth $34.3K as of Q2 2026.
First Horizon Corporation bought 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
Alnylam Pharmaceuticals made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2026, its #820 holding.
First Horizon Corporation first reported a position in Alnylam Pharmaceuticals in Q3 2020 and has held it in 8 quarters since.
First Horizon Corporation's Alnylam Pharmaceuticals position peaked at $64.8K in Q4 2025.
262 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on First Horizon Corporation's 13F filing for Q2 2026, filed 20 Jul 2026.